Replies to post #516601 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

The common ingredient in all of Dr. Liau's combo trials is DCVax-L. Enough said.

[biosectinvestor]

Your post is absurd:

https://www.uclahealth.org/medical-services/neurosurgery/brain-tumor/treatments/biologics

$NWBO news: Dr. Linda Liau presented the #DCVax-L Phase III trial results on 7/1/2022 in Prague, Czech Republic at The Society of University Neurosurgeons 2022 Annual Meeting: https://t.co/DElAm2ZYZM pic.twitter.com/lpgtGDHPPk

— ATLnsider (@ATLnsider) July 11, 2022

[The Danish Dude]

Dr. Liau is not exactly giving DCVax-L an endorsement in UCLA's latest GBM newsletter:

"Dr. Liau says treatment resistance can be caused by the therapy itself, including radiation, chemotherapy and immunotherapy."

“For instance, when giving immunotherapies, we can induce T cells that go attack the tumor,” she says. “But this can trigger a new population of immune suppressor cells that attack the T cells. Even though we’re inducing an immune response against tumors cells, the body is fighting back to protect against an immune attack in the brain.”

There's a quote, "... like the devil reads the bible", which points to a selective skimming of a given text. I believe, you missed out a few spots and the entire meaning of said article.

Let's have a closer look at, what was the main point of what Linda Liau actually said in the article.

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/



Which was essentially just a reiteration of what she has been saying in the three presentations during the last year, that they are seeing immense progress and astounding results, when combining DCVax-L with adjuvants, like Resquimod and Poly-ICLC in the combo trial started in 2010, which has been running for 12 years now and with 2 years remaining, where Linda Liau stated in her last presentatuis:



Let's talk about the endorsement of DCvax-L she made in her book, released April 2021.





We are WAY past the point where it is possible to insinuate, that Linda Liau is distancing her from either DCvax-L and Linda Powers and theories about herself making her own vaccine.

That was highly entertaining a year ago, but since then, we've been drowned in facts about DCvax-L being the secret ingredient in the SPORE 1 UCLA project with Keytruda and we now also know about the 12 year long combo trial with Resquimod and Poly-ICLC.

DCVax is positioning itself as an ingredient, that somehow gets much more efficient when added to the compound of checkpoint inhibitors and adjuvants, with drastically enhanced efficacy, even when compared to how it is a landmark result by itself, much better than anything during the last 27 years.

[hoffmann6383]

LOLOL at this bullshit

[SkyLimit2022]

Thank you for posting an excerpt of the latest update from the NIH NCI funded work at UCLA. Here is the link so that everyone can read the entire article:

September 14, 2022 Update of NIH NCI Funding of Dr. Liau

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

9/14/2022
In a trial now underway, a dendritic cell vaccine is made from a participant's own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.

"What I'm excited about is that we're seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations," Dr. Liau says. "We're seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we're trying to find out what combination works best and for which patients."

https://cancer.ucla.edu/research/ucla-brain-spore

[JMarv]

Def. BS

[Roman516]

Contrary to personal opinions as this is old news with respect to DCVax-L and Dr. Linda Liau.

https://cancer.ucla.edu/Home/Components/News/News/1144/1631

DCVax-L is a DC vaccine as you already know, and Dr. Liau continues her research supporting DCVax-L including adding additional products to help fight resistive GBM.

[Hspooner]

You are so simple!